Lexeo Therapeutics (LXEO) Income from Continuing Operations (2022 - 2026)
Lexeo Therapeutics (LXEO) posted Income from Continuing Operations of 20196000.0 for Q1 2026, up 12.11% sequentially from 22980000.0 in Q4 2025, and up 38.16% YoY from 14618329.99 in Q1 2025.
Lexeo Therapeutics (LXEO) Income from Continuing Operations (2022 - 2026) Analysis & Trends
Lexeo Therapeutics has reported Income from Continuing Operations for 5 years, with the latest figure at 20196000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 38.16% year-over-year to 20196000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 89562000.0 (up 18.06% YoY) and the FY2025 annual result came in at 222062000.0, down 125.83% from the prior year.
- Income from Continuing Operations advanced to 20196000.0 in Q1 2026 per LXEO's latest filing, from 22980000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 13441000.0 in Q2 2023 and troughed at 32656000.0 in Q1 2025.
- A 5-year average of 21238400.0 and a median of 20283000.0 in 2025 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2024 and 2026: Income from Continuing Operations sank 82.73% in 2024, then soared 38.16% in 2026.
- Over 5 years, Income from Continuing Operations stood at 14577000.0 in 2022, then rose by 2.68% to 14187000.0 in 2023, then sank by 82.73% to 25924000.0 in 2024, then increased by 11.36% to 22980000.0 in 2025, then climbed by 12.11% to 20196000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 20196000.0, 22980000.0, and 20283000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Lexeo Therapeutics | 397.10 Mn | 397.10 Mn | - | -25.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -25.87 Mn |
| Mar 31, 2026 | -20.20 Mn |
| Dec 31, 2025 | -22.98 Mn |
| Sep 30, 2025 | -20.28 Mn |
| Jun 30, 2025 | -26.10 Mn |
| Mar 31, 2025 | -32.66 Mn |
| Dec 31, 2024 | -25.92 Mn |
| Sep 30, 2024 | -29.49 Mn |
| Jun 30, 2024 | -21.24 Mn |
| Mar 31, 2024 | -21.68 Mn |
| Dec 31, 2023 | -14.19 Mn |
| Sep 30, 2023 | -20.11 Mn |
| Jun 30, 2023 | -13.44 Mn |
| Mar 31, 2023 | -18.66 Mn |
| Dec 31, 2022 | -14.58 Mn |
| Sep 30, 2022 | -17.06 Mn |